This finding suggests that the heterodimer of wild-type and mutant EGFR molecules might be formed in non-small cell lung cancer cells, thereby affecting the binding of selective tyrosine kinase inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.